

# GH-transgenic Nile tilapia case study

## About the fish

- This line expresses a single copy of an *opAFPcsGH* (ocean pout antifreeze polypeptide promoter - Chinook salmon growth hormone) transgene (Rahman et al. 2001).
- In a growth trial, the transgenic tilapia showed a 2.5-fold increase in growth compared with non-transgenic siblings.



- Food conversion efficiency was >20% greater in the transgenic fish.
- A digestibility trial suggested that transgenic tilapia were more efficient utilizers of protein, dry matter and energy.
- A company has purchased the license to market this line, and now wants to market it to commercial producers in your country.
- *Would you approve? If so, with any restrictions?*
- Rahman et al. 2001. Growth and nutritional trials on transgenic Nile tilapia containing an exogenous fish growth hormone gene. Journal of Fish Biology 59:62-78.

## Simplified risk assessment – risk management framework

Define conceptual model(s) of the system

Define assessment endpoints (harms)

Identify and prioritize risk pathways

Agree on assessment methods, models

Estimate risk: Assess exposure. Assess likelihood of harm being realized.  $R = P(E) \times P(H|E)$ .

Is risk acceptable?

Yes – approve. Communicate risk.

No – identify and evaluate other risk management options.

Monitor outcome indicators.



Is outcome acceptable?

No. Reevaluate. Perhaps stop the activity.


Yes.

# Risk assessment

## Pathway for assessing genetic harm



## Pathways for assessing ecological harm



## Risk management

Physical/chemical barriers (temp, pH)

Mechanical barriers (screens, filters)

Biological barriers (→ survival or reproduction of GM fish)

Operations management (fish handling procedures, limited access, maintenance)

